16 June 2021 - - US-based diagnostic solutions company Biodesix, Inc. (NASDAQ: BDSX) has undertaken the broad commercial launch of a SARS CoV-2 Neutralization Antibody Test (cPass Neutralization Test Kit, GenScript Inc.), the company said.

The test uses ELISA technology to detect circulating neutralizing antibodies against the receptor binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) and is the first and only surrogate neutralizing antibody test with FDA Emergency Use Authorization.

The cPass test represents an important diagnostic solution to understanding long-term protective immunity to SARS-CoV.

Current vaccines have been proven highly effective at generating antibodies against the viral spike protein when administered as recommended.

However, despite significant research and clinical advances made to combat the SARS-CoV-2 virus, the emergence of new variants and community outbreaks are of continued concern and have been observed in both previously infected and vaccinated individuals.

Neutralizing antibodies produced by the body's immune system may specifically block the interaction between the receptor binding protein on SARS-CoV-2, and the host cell's membrane receptor protein, thereby preventing infection of the cell by the virus.

The Biodesix SARS CoV-2 Neutralization Antibody Test has the potential to identify in individuals, the presence (or absence) of this important subset of antibodies that arise after previous infection or vaccination.

Healthcare providers may use the presence of neutralizing antibodies to understand whether an immunized individual is positive or negative for SARS-CoV-2 neutralizing antibodies, which may be of particular importance on how immunocompromised patients are managed.

Biodesix is a diagnostic company with a focus in lung disease. The company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence.

Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung. Biodesix launched the Bio-Rad SARS-CoV-2 ddPCR test, the Platelia SARS-CoV-2 Total Ab and the cPass SARS CoV-2 Neutralization Antibody Test in response to the global pandemic caused by SARS-CoV-2, the virus that impacts the lung and leads to COVID-19.

The antibody tests can detect antibodies that are generated both from infection by the virus and from the vaccines.
The blood-based Biodesix Lung Reflex strategy for lung cancer patients integrates the GeneStrat and VeriStrat tests to support treatment decisions with results in 36 hours, expediting time to treatment.

The blood-based Nodify Lung nodule risk assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action.

Biodesix also collaborates with many of the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.